On February 28th, American pharmaceutical company AbbVie announced the establishment of a strategic partnership with France's OSE Immunotherapeutics to jointly develop a novel monoclonal antibody drug named OSE-230, which is aimed at treating chronic inflammation. It is reported that OSE-230 is the world's first monoclonal antibody to target the activation of a member of the GPCR family, the chemerin receptor (ChemR23), and is anticipated to offer a new mechanism for addressing chronic inflamma

Since its first approval in the United States in August 2019, Upadacitinib has rapidly scaled up to become a blockbuster drug within just two years. Sales reached $1.65 billion in 2021, $2.5 billion in 2022, and $1.604 billion in the first half of 2023, an increase of 51.7% year-over-year. With the approval of new indications and the expansion of its approved uses, AbbVie predicts that sales of Upadacitinib will exceed $7.5 billion by the year 2025. Introduction to Upadacitinib Upadacitinib was

Over the past year, peptide-based pharmaceuticals have garnered significant market attention. On one hand, GLP-1 peptide drugs have sparked the treatment market for obesity and metabolic diseases; on the other hand, several nuclear medicine companies, long dedicated to the development of peptide-receptor radionuclide therapy (PRRT), have been successively acquired by international pharmaceutical giants. This article provides an interpretation of a review published in the 2021 issue of "Nature R

On 25 Jan 2024, the rate of hospitalization and length of hospital stay during and post docetaxel for darolutamide in metastatic hormone-sensitive prostate cancer (darolutamide (daro) + docetaxel + androgen deprivation therapy (ADT) vs. placebo (pbo) + docetaxel + ADT) was reported in the 2024 ASCO_GU. Darolutamide's R&D Progress Darolutamide is a small molecule drug that targets the androgen receptor (AR). It has been approved for use in various therapeutic areas, including neoplasms, urogen

TAR-210 is an intravesical drug delivery system that is designed to provide local, continuous release of erdafitinib. Its safety and efficacy are being evaluated in a first-in-human clinical study (NCT05316155) of patients with bladder cancer whose tumors harbor select FGFR alterations (alt). Toovercome tissue-based challenges in identifying susceptible FGFRalt to select patients for treatment with TAR-210, Janssen partnered with Predicine to use a proprietary urine cell-free DNA diagnostic assa

Gastric Cancer (GC), also known simply as GC, is one of the most lethal malignancies worldwide, with over one hundred million new cases reported in 2022, leading to the death of 783,000 individuals. Globally, the incidence and mortality rates of gastric cancer have been on the decline in most regions over the past few decades. This considerable change is largely attributed to economic development and improved practices in food preservation associated with refrigeration technology during food tra

In the subset of patients with UC bearing alterations in the fibroblast growth factor 3 (FGFR3) gene, targeted therapies directed at this moiety have shown substantial antitumor effect in the metastatic setting. The 2024 ASCO_GU reported the latest clinical trial results of infigratinib, a potent and selective inhibitor of FGFR3, illustrating its potential clinical benefits. Infigratinib's R&D Progress Infigratinib is a small molecule drug that targets FGFR1, FGFR2, FGFR3, and FGFR4. The drug

Myristoylation catalyzed by N-myristoyltransferases (NMT) 1 and 2 regulates membrane-bound signaling important in cancer, including Src and Src-family tyrosine kinases. Zelenirstat is a potent oral small molecule pan-NMT inhibitor. And the latest clinical results of Zelenirstat for the treatment of relapsed/refractory advanced cancer were presented in 2024 ASCO_GI. Zelenirstat's R&D Progress Zelenirstat is a small molecule drug that targets NMT1 and NMT2. It falls under the therapeutic areas of

Tinengotinib is a spectrum-selective multi-kinase inhibitor with unique binding properties to FGFR, potently inhibited FGFR2 fusion/rearrangement and acquired resistant mutations in pre-clinical models and in phase I trials that included cholangiocarcinoma (CCA) patients (pts). Recently, the promising anti-tumor efficacy of tinengotinib in a phase II clinical trial was reported in the 2024 ASCO_GI. Tinengotinib's R&D Progress Tinengotinib is a small molecule drug that targets multiple proteins

APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities. Single-agent neoadjuvant programmed death 1 (PD-1) antibodies achieve pathological complete responses in a subset of patients (pts) with muscle-invasive bladder cancer (MIBC). APL-1202 and PD-1 antibody combination therapy demonstrates synergistic effects in several model systems of cancer, including bladder cancer. Recently, the clinical results of Nitroxoline, in combina